Summary. Three hundred isolates of Staphylococcus aureus from wound swabs were examined for the production of toxic shock syndrome toxin 1 (TSST-1). The isolates were collected from community patients, surgical inpatients and from patients in the Regional Burns Unit, Booth Hall Children's Hospital, Manchester. The overall incidence of toxin production was 17 % and there was no significant variation between the sources of the strains. All 55 TSST-1 -producing strains were grown in sublethal concentrations of five topical antimicrobial compounds and the level of toxin produced was determined and compared with the amount produced in a control broth after incubation for 24 h. The effects of sublethal concentrations of the compounds on TSST-1 production were strain dependent ; some compounds tended to increase production (at least four-fold) and some tended to decrease production (at least fourfold). Some of the strains showed an increase in toxin production in the presence of chlorhexidine gluconate/cetrimide solution and silver sulphadiazine cream whereas 18 Yo, 42% and 47% of the strains showed a decrease in toxin production in the presence of povidone iodine solution, stabilised hydrogen peroxide cream and mupirocin ointment, respectively. Preliminary results suggest that silver sulphadiazine cream induces toxin formation earlier in the growth cycle.
Introduction
Toxin shock syndrome (TSS) is a sequel of infection caused by TSST-1 -producing strains of Staphylococcus aureus.' Although primarily associated with tampon use,2 there have been many cases of non-menstrual TSS following various infection^,^ in particular infected Staphylococcal enterotoxins B and C (SEB and SEC) have also been implicated as causes of TSS'.' although the incidence is far lower than with TSST-1 .' TSS is a consequence of several factors. The patient has to have an infectious focus and be susceptible to the toxin, and suitable environmental conditions must prevail for the organism to produce the toxin.' It has been shown that toxin production can be affected by various environmental factors including temperature, oxygen availability, pH of the medium, nature of the tampon, magnesium concentration and the presence of blood and p r~t e i n . '~-'~ The large open wound which results from a burn may provide conditions that could stimulate toxin production.
In this study, the incidence of toxin production in Received 12 Oct. 1993; revised version accepted 10 June 1994.
the three groups of isolates was determined and the effects of topical antimicrobial compounds on the production of TSST-1 by S. aureus were investigated. Previous worker^'^,'^ have found that c. 20% of all S. aureus isolates produce TSST-1.
Materials and methods

Collection of strains
Three hundred isolates of S. aureus were collected over a 6-month period from wounds of patients, irrespective of age, sex or site of infection. Three distinct sources were used : (1) community patients from Bury, Lancs; (2) hospital inpatients (surgical and medical wards) in the Bury and Fairfield Hospitals, Bury, Lancs; and (3) patients admitted to the Regional Burns Unit, Booth Hall Children's Hospital, Manchester. One hundred isolates were collected from each source.
All strains were confirmed as S. aureus by coagulase and DNAase tests. All isolates were then preserved on beads in tryptone glycerol buffer (TSC Protect TS/70) and stored at -70°C to maintain viability and phenotypic properties. 
Toxin production
Five control strains were used (Tl-T5, table I ). These, together with the 300 clinical strains were grown in 20 ml of Brain Heart Infusion Broth (BHI; Oxoid CM 225) in 50-ml Erlenmeyer flasks in an orbital incubator rotating at 200 rpm at 37°C for 24 h.
Toxin production by each strain was assessed by Reverse Passive Latex Agglutination (RPLA) kits from Unipath (TD 40) used according to the manufacturer's instructions. l6 The assay is semi-quantitative and results are given as the lowest dilution that gave agglutination (titre). Within each experiment the same kit was used to ensure comparability.
Determination of sublethal concentrations of antimicrobial agents
The following compound preparations were chosen primarily for their different pharmaceutical properties and different modes of action: povidone iodine lo%, antiseptic solution (Betadine; Napp Laboratories, The minimal inhibitory concentrations (MICs) were determined for all 55 TSST-1 positive strains by multipoint inoculation of DST Agar (Oxoid CM 261) containing aqueous dilutions of the preparations. Some of the cream preparations were difficult to dissolve in water and, therefore, were used as a suspension, which was well mixed before addition to the media. The MIC was recorded as the lowest dilution of the compound that inhibited growth of the organism after incubation for 18 h.
Toxin production in sublethal concentrations of compounds
A sublethal concentration of each compound was chosen that allowed growth of the majority of the toxin-positive strains and all of the control strains (see table 111 ). BHI (10 ml) containing an aqueous dilution of the compound at the chosen sublethal concentration and a control broth (BHI only) were inoculated with a standard inoculum derived from a washed overnight broth culture of strains T1-T5 and incubated in 30-ml screw-capped containers for 24 h in an orbital incubator (37"C, 200rpm). All tests were set up in triplicate. After incubation for 24 h, viable counts and toxin estimations were determined and compared to their respective control broths. Subsequent testing of the other 50 positive isolates was done at the same sublethal concentration, but, due to limitation of toxin reagents, was performed only as a single assay with strains T1-T5 as batch controls.
Production of toxin during the growth cycle
Silver sulphadiazine 1 YO cream and mupirocin 2 YO ointment were chosen for further study because of their frequency of use on the burns patients. The control strain of S . aureus (T4) isolated from a confirmed case of TSS in a burns patient was used in this experiment because of its marked response to the compounds. An overnight broth culture of strain T4 was washed three times in saline to remove any residual toxin and a standard inoculum was added to the following in 100-ml Erlenmeyer flasks: (i) 100 ml of BHI; (ii) 100 ml of BHI containing silver sulphadiazine 1 O/ O cream 2-5 g/L; (iii) 100 ml of BHI containing mupirocin 2 Yo ointment 0.005 g/L. All experiments were done in triplicate.
At time 0 h, a 1-ml sample was taken from each broth for viable count and toxin estimation. The broths were placed in an orbital incubator at 200 rpm and 37°C for 24 h. Samples (1 ml) were removed at 2-h intervals throughout the 24-h period. Surface viable counts and the amount of toxin production were determined.
Statistical analysis
of numbers of organisms and toxin production.
The paired Student's t-test was used for comparison
Results
Incidence of TSST-1 produc tiotz
The overall incidence of TSST-1 production in the 300 strains tested was 17 O h (50 strains). The incidence of toxin production from hospital inpatients, outpatients and patients from the burns unit was 19, 15 and l6%, respectively. There was no significant difference between the groups (p > 0.050).
Susceptibility to antimicrobial agents and toxin production in sublethal concentrations
The MICs of the topical antimicrobial compounds are shown in table 11. The MIC for the active ingredient is proportional to the percentage present within the compound. The strains showed a wide variation in 
Silver The total compound was diluted to the concentrations shown. Actual concentrations of the active ingredient are proportional to the percentage present in the compounds. susceptibility to silver sulphadiazine 1 % cream and chlorhexidine gluconate/cetrimide solution but with other compounds, MICs were typically in a narrow range of concentrations. When the levels of toxin production of all isolates were compared to levels in the respective control broths, there was a marked variation between strains, with some strains showing an increase in toxin production, some a decrease and some no effect. Results for strains T1-T5 are shown in table IV. In one strain (T4), silver sulphadiazine cream enhanced toxin production eight-fold and mupirocin ointment decreased toxin production 16-fold. The percentage of the 50 strains affected by each compound for toxin production, compared to the respective control broth, is shown in table VI. A four-fold difference in levels of toxin production was taken as an indication of change. Mean titres of toxin production are shown in table V.
Production of toxin during the growth cycle
Toxin production occurred at the end of exponential phase in the control broth and showed a rapid increase in levels which reached a maximum after 20 h and remained constant up to 24 h ( fig. 1 ). Toxin production was depressed 16-fold after 24 h in the presence of mupirocin ointment, without producing a significant difference in the viable count compared to the control broth ( fig. 2) . The toxin was only just detectable after 24 h. Toxin production was increased eight-fold after 24 h in the presence of silver sulphadiazine cream, 
Fig. 2. Viable count (-W-)
and production of TSST-1 (-lJ-) by S. aureus strain T4 during growth in the presence of mupirocin 2%. and production of TSST-1 (-rJ-) by S. aureus strain T4 during growth in the presence of silver sulphadiazine 1 YO.
without producing a significant difference in viable count compared with the control broth ( fig. 3) . Toxin production occurred earlier in the growth cycle and reached much higher levels than in the control.
Discussion
The incidence of TSST-1 production by the isolates of S. aureus was comparable with that described by previous workers.14* l5 The incidence of TSST-l-producing strains of S . aureus in the Regional Burns Unit has not been determined previously and the results of this study indicate that this was not significantly different from strains isolated from other areas. This would seem to indicate that there must be other factors responsible for the increased risk of developing TSS in burns. TSS is a multifactorial syndrome and any one of many causes could be responsible. Of the children admitted to the Regional Burns Unit, 80% are under the age of 5 years (personal communication, Regional Burns Unit patient database) and studies in the USA on the incidence of antibodies in the general population show that antibody status increases with age.17
This implies that as many as 50 of the patients could be TSST-1 antibody negative and thus at risk if they become infected with a TSST-1-producing strain of S. aureus. The antibody status of the burned child to TSST-1 toxin could be a major factor in the resulting syndrome. Several environmental conditions stimulate S. aureus to produce increased amounts of toxin and it is possible that similar responses are occurring at the wound site in the susceptible burns victim. The possibility that topical antimicrobial agents applied to the wound subsequently stimulate the S. aureus isolate to produce toxin has been assessed in this study. In the areas of the wound where there are high levels of antimicrobial compound the organism would be killed or its growth markedly affected. In deeper areas or at the outer edge of the burn where the bactericidal concentration was not achieved, it is possible that S. auraus could survive, grow and produce toxin, thus increasing the risk of TSS to the child. The physical condition of the wound depends upon the burn itself; however, within a very short time period, oedema is formed due to plasma leakage and although at a level less than in plasma, protein is present.'* The level of protein may increase as the burn ages due to eschar formation and coagulum production. Blood may or may not be present. Both blood and protein have been shown to favour toxin production,13 therefore an enriched medium (BHI) known to favour TSST-1 production was chosen for growth in vitro. It is difficult to achieve an in-vitro model for a burn wound as there are so many variables depending upon the nature and condition of the burn and the patient. The results of this study indicate that, in an enriched growth medium, toxin production can be enhanced or depressed depending upon the topical antimicrobial compound used, but this effect may not be reflected in vivo. This area needs further investigation with an appropriate animal model before any definitive deduction can be made.
The strains reacted differently to the sublethal concentrations of the antimicrobial compounds; the effect depended upon the compound used. Stabilised hydrogen peroxide cream and chlorhexidine gluconate/cetrimide solution increased toxin production in some strains, yet in other strains production was decreased. Povidone iodine solution, which is used often on burns, decreased production in 18 Yo of the strains but the majority of strains showed no variation. However, silver sulphadiazine cream, which is used routinely for the treatment of burns," caused an increase in toxin production of at least fourfold in the presence of a sublethal concentration of the compound in 45% of the strains. On the other hand, mupirocin ointment caused a marked decrease in toxin production in 47 O/ O of the strains and did not cause an increase in toxin production in any of the strains. These results suggest that some antimicrobial agents used may be increasing toxin production and hence the incidence of TSS, whereas others even at sublethal concentrations can depress toxin production. Only one sublethal concentration was chosen for each compound, and the response seen in this study may have differed if other concentrations had been chosen, i.e., the optimum concentration may differ for each strain. This is being investigated currently.
The production of toxin occurs at the end of the exponential phase under the influence of the agr regu10n.l~ Batch culture of the organism over a 24-h period showed that, in the presence of silver sulphadiazine cream, growth of the organism occurred at a similar rate but that toxin production occurred far earlier in the growth cycle ( fig. 3) and not at the end of the exponential phase, as in the control culture. The resulting levels were eight-fold greater than in the control broth. Mupirocin ointment showed a longer lag phase in the growth cycle and after a 24-h period appeared to have just reached stationary phase, resulting in organism numbers similar to the control broth but marked depression of toxin production ( fig.  2 ) * Silver sulphadiazine is the active ingredient in Flamazine20 but there are also many other chemicals included in the carrier creams. The silver sulphadiazine dissociates slowly in the wound, releasing silver ions over a period. The sulphadiazine molecule, although a folic acid inhibitor, is at concentrations well below normal MIC levels. Studies have shown that the sulphadiazine moiety at sublethal levels appears to affect membrane permeability.21 The silver ions have been shown to act as intercalating agents and distort the shape of DNAz2 and also to affect cell-envelope p r o d u~t i o n .~~ It is possible that this compound at sublethal levels allows better transport of silver ions across the cell membrane, as previously reported,2' and then this has some beneficial effect on TSST-1 synthesis, either at the level of expression of the gene or subsequent production and release under the control of the cell membrane. It is also possible that any previously recorded effects of silver on the cell may be very different at subinhibitory concentrations, as most molecular studies have been performed at inhibitory levels.
In contrast, mupirocin-the active ingredient in Bactroban-has a completely different mode of action and acts at the level of translation by inhibition of protein synthesis by competitive inhibition of isoleucyl transfer RNA ~y n t h e t a s e .~~ Inhibition of protein synthesis has been shown to induce TSST-1 ~ynthesis'~ but this effect was clearly not shown by mupirocin cream.
It is not known why some strains showed increased toxin synthesis whereas others were not affected. It is possible that there are genetic differences between the strains. Alternatively, all strains were tested at only a single concentration and may show a similar response at a different concentration. This aspect is currently under investigation. The topical agents contain other compounds a vehicles for the active ingredients and we are also investigating whether these agents contribute to the observed effects.
